Array comparative genomic hybridisation (aCGH) RGCC
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. aCGH RGCC can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.
Purpose of the test
Purpose of the test
Scientists have established that if crucial parts of the genetic sequence in a chromosome are deleted or added to, it can lead to cancer developing. aCGH RGCC is designed to identify and chromosomal abnormalities that could cause cancer, and their potential location.
The power of aCGH RGCC comes in its precision: it’s the most accurate test of its type available today. The results of the test provide a unique and personalised chromosomal analysis that can be used by clinicians to help patients understand more about their risk of developing cancer.
Useful information
Useful information
Recent developments in genetics enable scientists to study chromosomes in incredible detail. aCGH RGCC uses a technique called comparative genomic hybridisation to identify abnormalities. The DNA of a patient is compared to a sample to identify any abnormalities.
aCGH RGCC requires 7-10 ml of whole (peripheral) blood, to be sent in an immobilising liquid in a 10ml volume vial tube. RGCC can provide a sampling kit including a vial tube, and detailed instructions on how to collect and send samples, upon request (see below).
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on how to access, perform or analyse the results of aCGH RGCC test, then get in touch today.